Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors
作者:Ji Zhou、Li-Zhen Yu、Ya-Li Fan、Ci-Hao Guo、Xiao-Mei Lv、Zhi-Yin Zhou、Hui-Dan Huang、Dong-Dong Miao、Sheng-Peng Zhang、Xin-Yu Li、Ping-Ping Zhao、Xiao-Ping Liu、Wei-Hua Hu、Chao Zhang
DOI:10.1016/j.ejmech.2022.114860
日期:2023.1
antitumor agents, novel dual indoleamine 2,3- dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) inhibitors were designed. Thioredoxin reductase 1 (TrxR1) is a main ROS modulator within CRC cells. Indoleamine 2,3-dioxygenase (IDO1) is crucial controller for tryptophan (Trp) metabolism that is also important for CRC immunotherapy. Herein, ten compounds 12a-j containing hydroxyamidine scaffold were designed
为了利用免疫治疗和代谢抗肿瘤药物的优势,设计了新型双重吲哚胺 2,3-双加氧酶 1 (IDO1) 和硫氧还蛋白还原酶 1 (TrxR1) 抑制剂。硫氧还蛋白还原酶 1 (TrxR1) 是 CRC 细胞内的主要 ROS 调节剂。吲哚胺 2,3-双加氧酶 (IDO1) 是色氨酸 (Trp) 代谢的关键控制器,对于 CRC 免疫治疗也很重要。在此,设计、合成了十种含有羟基脒支架的化合物12a-j ,并评估了其对 IDO1/TrxR1 酶和 CRC 细胞的抑制活性。在这些化合物中,活性最强的化合物12d (ZC0109)对 IDO1 (IC 50 = 0.05 μM) 和 TrxR1 (IC 50 = 3.00 ± 0.25 μM) 被选择用于进一步评估。化合物ZC0109在体外和体内均对IDO1和TrxR1表现出良好的双重抑制作用。进一步的机制研究表明,通过ZC0109处理抑制 IDO1 和 TrxR1,累积的